Detalhe da pesquisa
1.
A Comparative Study Evaluating the Quality of Life and Survival Outcomes in Patients Receiving Chemotherapy Versus Oral Tyrosine Kinase Inhibitor in the Third Line and Beyond Setting for Advanced NSCLC.
JTO Clin Res Rep
; 5(1): 100622, 2024 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-38292414
2.
Gemcitabine, Cisplatin, and Nab-Paclitaxel as a First-Line Therapy for Advanced Biliary Tract Cancers.
J Gastrointest Cancer
; 2023 Jun 27.
Artigo
Inglês
| MEDLINE | ID: mdl-37368175